| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
The Oregon Clinic is the largest private specialty physician practice in Oregon, with more than 200 providers practicing over 30 different medical and surgical specialties and sub-specialties. An evidence-based, multidisciplinary organization, The Oreg...
Rx Biotech Specialty Pharmacy is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PDi-Pharmaceuticals is a Aurora, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tjoapack is a contract packaging organisation which specialises in developing innovative primary & secondary packaging solutions for the pharma supply chain.